Manufacturing / Pharmaceutical Preparations
MIRA PHARMACEUTICALS, INC.
MIRA
$0.72
+$0.01 (+2.08%)
Price as of Oct 9, 2026 16:12 UTC
33 M
Market Cap (Micro Cap)
Nov 11
Next Earnings
Technical Signals
as of Oct 7
Bearish
0 of 7
Trend
- Above 20-day average $0.79
- Above 50-day average $0.81
- Above 200-day average $1.04 · -31.6%
- Moving averages stacked Not aligned
Momentum
- Golden cross (50/200) —
- Momentum cross (20/50) Down · 4d ago
Volume
- Below-average volume 0.4x avg
Price & Trend
Daily candles with EMA 20, SMA 50. Drag to zoom.
Options Heat Map
Delta-risk grid for MIRA options across strikes and expirations. Hover any cell for full Greeks.
Loading option chain data...
Insider Trades
0 buys
1 sells
| Date | Insider | Title | Type | Shares | Value | Since Trade |
|---|---|---|---|---|---|---|
| Jun 12, 2026 | Del Giudice Matthew Paul | Grant | 50,000 | $0 | -25.5% | |
| Jun 12, 2026 | MacPherson Edward Clouston | Grant | 50,000 | $0 | -25.5% | |
| Jun 12, 2026 | MacPherson Edward Clouston | Other | 50,000 | $0 | -25.5% | |
| Jun 12, 2026 | Del Giudice Matthew Paul | Other | 50,000 | $0 | -25.5% | |
| Jun 12, 2026 | Shekhat Denil Nanji | Other | 50,000 | $0 | -25.5% | |
| Jun 12, 2026 | Shekhat Denil Nanji | Grant | 50,000 | $0 | -25.5% | |
| Jun 12, 2026 | Whalen Matthew Pratt | Grant | 50,000 | $0 | -25.5% | |
| Jun 12, 2026 | Whalen Matthew Pratt | Other | 50,000 | $0 | -25.5% | |
| Mar 30, 2026 | Aminov Erez | Grant | 83,500 | $0 | -27.1% | |
| Mar 30, 2026 | Aminov Erez | Other | 83,500 | $0 | -27.1% |
Earnings History
| Date | Quarter | EPS Est. | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Aug 12, 2026 | Q2 2026 | ||||
| Jun 30, 2026 | Q2 2026 | -$0.03 | |||
| May 12, 2026 | Q1 2026 | ||||
| Sep 30, 2025 | Q3 2025 | -$0.08 | -$0.06 | +26.5% | Beat |
| Jun 30, 2025 | Q2 2025 | -$0.13 | -$0.09 | +32.1% | Beat |
| Mar 31, 2025 | Q1 2025 | -$0.15 | -$0.11 | +25.6% | Beat |
| Dec 31, 2024 | Q4 2024 | -$0.24 | -$0.15 | +37.4% | Beat |
Track MIRA with ThetaPal
Get insider trade alerts, AI portfolio analysis, and options roll recommendations for MIRA and your entire portfolio.